×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [28]
合肥物质科学研究院 [13]
大连化学物理研究所 [6]
北京大学 [5]
高能物理研究所 [4]
昆明动物研究所 [4]
更多...
内容类型
期刊论文 [81]
学位论文 [6]
会议论文 [2]
其他 [1]
发表日期
2023 [1]
2022 [3]
2021 [2]
2020 [7]
2019 [7]
2018 [5]
更多...
学科主题
物理化学 [3]
Biophysics [1]
Plant Scie... [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共90条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Morphological and physicochemical characteristics, biological functions, and biomedical applications of diatom frustule
期刊论文
ALGAL RESEARCH-BIOMASS BIOFUELS AND BIOPRODUCTS, 2023, 卷号: 72, 页码: 13
作者:
Yang, Chenfei
;
Feng, Chao
;
Li, Yuhang
;
Cao, Zheng
;
Sun, Yan
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2023/12/13
Diatom
Frustule
Morphological feature
Biological function
Biomedical application
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
期刊论文
BMC Medicine, 2022, 卷号: 20, 期号: 1
作者:
Zhang,Pei
;
Du,Yang
;
Bai,Hua
;
Wang,Zhijie
;
Duan,Jianchun
收藏
  |  
浏览/下载:123/0
  |  
提交时间:2022/11/21
Tucidinostat
Tumor microenvironment
PD-L1
CCL5
Solid tumor
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
期刊论文
FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13
作者:
Wu, Xiaofan
;
Yang, Hongjian
;
Yu, Xingfei
;
Qin, Jiang-Jiang
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2022/12/22
HER2
breast cancer
targeted therapy
drug resistance
overcoming strategies
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers
期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:
Cao, Jiang-yan
;
Qi, Shuang
;
Wu, Hong
;
Wang, Ao-li
;
Liu, Qing-wang
收藏
  |  
浏览/下载:92/0
  |  
提交时间:2022/03/28
HER2
breast cancers
gastric cancers
irreversible inhibitor
drug resistance
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
期刊论文
ADVANCED MATERIALS, 2021, 页码: 37
作者:
Saeed, Madiha
;
Chen, Fangming
;
Ye, Jiayi
;
Shi, Yang
;
Lammers, Twan
收藏
  |  
浏览/下载:37/0
  |  
提交时间:2021/08/17
clinical translation
nanobiomaterials
nanovaccines
normalization cancer immunotherapy
primary and adaptive resistance
tumor immune microenvironment
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2
期刊论文
BLOOD ADVANCES, 2021, 卷号: 5, 期号: 1, 页码: 185-197
作者:
Wu, Wenjun
;
Wang, Weige
;
Franzen, Carrie A.
;
Guo, Hui
;
Lee, Jimmy
收藏
  |  
浏览/下载:44/0
  |  
提交时间:2020/07/01
Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation
期刊论文
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 卷号: 30, 期号: 16, 页码: 6
作者:
Su, Zhicheng
;
Yang, Tingyuan
;
Wang, Jie
;
Lai, Mengzhen
;
Tong, Linjiang
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2020/12/24
EGFR
NSCLC
C797S
DGAT1 inhibitors protect pancreatic beta-cells from palmitic acid-induced apoptosis
期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 8
作者:
Huang, Jun-shang
;
Guo, Bin-bin
;
Wang, Gai-hong
;
Zeng, Li-min
;
Hu, You-hong
收藏
  |  
浏览/下载:54/0
  |  
提交时间:2020/12/24
type 2 diabetes
DGAT1 inhibitors
pancreatic beta-cells
apoptosis
ER stress
inflammation
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:
Shi, Yuankai
;
Zhang, Shucai
;
Hu, Xingsheng
;
Feng, Jifeng
;
Ma, Zhiyong
收藏
  |  
浏览/下载:38/0
  |  
提交时间:2020/12/24
Alflutinib
NSCLC
EGFR T790M mutation
Efficacy
Safety
A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib
期刊论文
CANCER LETTERS, 2020, 卷号: 478, 页码: 45-55
作者:
Chen, Gege
;
Hu, Ke
;
Sun, Haiguo
;
Zhou, Jinfeng
;
Song, Dongliang
收藏
  |  
浏览/下载:97/0
  |  
提交时间:2020/07/01
Multiple myeloma
Bone marrow microenvironment
DNA damage
JAK2/STAT3 pathway
©版权所有 ©2017 CSpace - Powered by
CSpace